Junyuan Wang, Ph.D.

Co-Founder & CEO

Dr. Wang has strong leadership experience in global clinical development and medical research acquired through his work at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. His broad drug development experiences include therapeutic areas such as oncology, cardiovascular, neuroscience, immunology, and hematology. He has a stellar track-record in shaping global drug development strategy. He has played critical support for two successful new drug applications in the US and worldwide market authorization. One of the products that he led a team of over 20 people to support NDA reached annual sale of 5 Billion USD in 2017. Besides his many interaction with health authorities including FDA, EMA, he also played a critical role in many submissions for label extensions through PMDA and CFDA. He also has rich experience in partnering with key opinion leaders and vendors to foster data-driven decision making. He is well recognized for his deep understanding of ICH guidelines, GCP compliance, and trial quality control. He serves as a global expert for two CFDA/CDE ICH working groups. He also served in a leadership role in professional societies and in the programming committee of scientific conferences. 

Dr. Wang earned BS from the University of Science and Technology of China and PhD from Iowa State of University.

Bing Yan, M.D., MBA

Co-Founder & Chief Medical Officer

Dr. Yan was trained as a medical doctor and has been a pharmaceutical executive with 20 years of experience in Phase 1-4 drug and vaccine development, global health authority interactions, and post-approval activities. He was the global Vice-President and Head of Asia Pacific Clinical Research at Pfizer. Over the years, he has accumulated rich experience in multiple therapeutic areas including neuroscience, vaccines, anti-infectives, transplant, oncology, hematology, and men’s/women’s health and Metabolic disorders. He has demonstrated strategic leadership with diverse background in healthcare with top global pharmaceutical corporations. He has proven success in solving complex issues in multiple programs/projects to achieve business goals and is highly recognized for managerial skills to create and implement both clinical and medical initiatives in driving and collaborating with multi-disciplined international teams. Notably, he made outstanding contributions in global and Chinese biopharmaceuticals development, including Chinese and Japanese Prevennar13, Chinese Xalkori, Lyrica, Enbrel, Pristiq, Effexor, Xyntha new drug registrations under a very challenging regulatory environment.

Dr. Yan holds a doctorate in clinical medicine from Shanghai JiaoTong University Medical School/Ruijin Hospital and post-doc fellowship at Johns Hopkins University School of Medicine and Eastern Virginia Medical School.

Lihua Zheng, J.D., Ph.D.

Co-Founder & Chief Business Officer

Dr. Zheng is both an entrepreneur and a seasoned business advisor with extensive knowledge of technical, business and legal nature. He is particularly experienced in transactions for life sciences companies and has guided transactions valued in total several hundred million dollars in the past few years. Previously he founded and led a boutique New York law firm specialized in venture financing and intellectual property transactions. He started his legal career in a wall street international law firm where he assisted major investment banks with matters relating to public offerings by many biotechnology issuers on NASDAQ and emerging growth companies with their IP and general corporate matters.

Dr. Zheng graduated from Fordham University School of Law with Juris Doctor and from Baylor College of Medicine with PhD in Molecular and Human Genetics. He obtained Master of Science and Bachelor of Science both from Fudan University. He is licensed to practice law in the State of New York and at the United States Patent and Trademark Office.

Dr. Frank Fan

Senior Vice President & Head of Clinical Development Strategy

Dr. Fan was previously a senior consultant in a world-leading pharmaceutical research and development contract research organization. Prior to that, he was the head of the medical science service department for Greater China in the same organizaiton. He has nearly 20 years of experience in research and development pharmaceutical companies and has served as the head of a number of multinational biopharmaceutical companies in Greater China. He focuses on clinical research and development strategy planning, medical science support and project management for many new drugs.

Dr. Fan holds a Bachelor of Medicine degree from Capital Medical University and a Master of Business Administration degree from Cranfield University.

Dagang Chen(Doug) , Ph.D.

Senior Vice President of CMC & General Manager of Hangzhou site

Dr. Chen has more than 25 years experience in Biomedical research, bio-pharmaceuticals process development and production. Before joining AHT, he was VP of Business Operations of BeiGene Ltd. and VP of CMC Development of I-Mab Biopharma Co., Ltd..  He once served as the principal investigator and senior scientist at several biopharmaceutical companies in China and abroad, and was responsible for R&D and management, including antibody discovery, development of process and production. He had successful experience in team building, technical platform establishment and CDMO cooperation in effective project management and clinical development. In addition, he was responsible for business operation of biopharmaceutical production on a commercial scale, including plant construction, technical transfer, quality management and production operation, and public relations. He first authored more than 20 publications in international journals such as Science and was an inventors of related patents. He was awarded the Expert on Shanghai Thousands of Plans in 2018.

 Dr. Chen graduated from the department of biology of Fudan University, and earned a doctorate degree from Chinese Academy of Sciences Shanghai Institute of Materia Medica.

Qinying Zhao, Ph.D.

Vice President of Clinical Pharmacology

Dr. Zhao has more than twenty-five years of extensive experience in global clinical development and clinical pharmacology. As Director of Clinical Pharmacology at several large global pharmaceutical companies, she served as Global Clinical Pharmacology Lead at Johnson & Johnson and Pfizer. She is very experienced in clinical pharmacology strategy/execution and clinical development of innovative drugs, IND/DNA submissions, and interaction with US and European, emerging markets and global regulatory agencies. Dr. ZHAO is familiar with regulatory requirements of US, European, and global regulatory agencies. She has served as an expert representative of clinical pharmacology for marketed drugs in cardiovascular, pain, and inflammatory therapeutic areas at Pfizer.

Dr. Zhao earned a doctorate in pharmacokinetics from West Virginia University, and conducted postdoc research at the University of Pennsylvania. She also obtained Master of Science in Biopharmaceutics from China State Institute of Pharmaceutical Industry and Bachelor of Science in Pharmacy from Fudan University.

Jun Li, Ph.D.

Vice President of Pre-clinical

Dr. Li has ten years of clinical practice in orthopedic surgery and traumatology followed by fourteen years of experience in pre-clinical pharmacodynamics. She was previously director of pharmacodynamic research of Pre-clinical Antibody in the Treatment of Immune Diseases in Shenzhou Cell Medicine Technology Co., Ltd.; senior director/chief scientist on Preclinical Animal Model and Pharmacodynamic R&D Outsourcing Business, Massachusetts General Hospital; researcher on pre-clinical pharmacodynamics of endocrine diseases and bone metabolic diseases, Curis Pharmaceutical Co., Ltd.; Massachusetts Pre-clinical pharmacodynamic researcher of new drugs for osteoarthritis.

Dr. Li was initially trained as a medical doctor and later earned PhD in Biochemistry from the Faculty of Medicine of the University of Hong Kong. She completed a preclinical postdoctoral study on new drugs for bone immune diseases.

Yizhong Ren, Ph.D.

Director of Medical Science Liaison

Dr. Ren previously served as the Deputy Director of translational medicine, responsible for medical affairs and translational medicine at Betta Pharmaceuticals. He served as the Senior researcher and supervisor of BD for the translational medicine center of QIAGEN Suzhou from 2014 to 2016, promoting biomarkers for innovative pharmaceutical companies and their cooperation in accompanying diagnostics. He is engaged in research on tumor molecular diagnosis and innovative clinical drug development. He has a deep understanding of the current trends in international oncology drug development and crucial target, the development of molecular markers of tumor drugs and the clinical trials of oncology drugs.

Dr. Ren holds a bachelor’s degree in clinical medicine from Anhui Medical University, and doctor’s degree from the University of Science and Technology of China.

Juan Pan

Director of Data Management

Juan Pan has more than ten years experiences in new drug research and development and supported several new drugs successful listing. She served on an innovative biopharmaceutical company from 2017 to 2019, established a data management department, and supported the market approval of the first anti-PD-1 monoclonal antibody in China. Before that, she worked in international/domestic top pharmaceutical companies including Pfizer and Roche.

Juan Pan holds a master degree from China National Institute of Pharmaceutical Industry majoring in cardiovascular medicine.

Viola Chen

Vice President of Corporate Operations

Viola Chen has twenty years of experience in the China and Asia Pacific market. At Egon Zehnder International, the world’s top human capital consulting and management firm, she worked closely with Fortune 500 companies to enter China and Asia markets and successfully set up management teams. Focused on the healthcare industry since 2008, she led the China and Asia operation of a top life sciences industry management consulting firm based in Boston, where she assisted WuXi AppTech and Genscript to enter the North American and European markets. Working with international firms, including Merck and Sanofi, she led the search for and evaluation of key staff for positions in vaccines, medicine, and clinical operations in emerging markets. Viola Chen served as HRG in GSK where she built the operational models and teams for government relations, compliance and finance department, and as a key team member worked with the CFO and senior vice presidents of global compliance. She also worked in the consumer goods industry and top Internet enterprises in China, gaining rich experience in the TOC business model and local Internet thinking. Vioal Chen served as health service partner at Korn Ferry Hay Group and participated in the construction of private hospitals, a chain of clinics, and high-end pension projects follow up, gaining profound insight into China’s medical environment and patient needs.

Viola Chen graduated from Nanchang University Law School, and holds a Bachelor of Law degree.

Scroll to top